Table 4. pT-IL-6-IL-6R risk groups and CSS.
|
Prognostic group |
|||||||
|---|---|---|---|---|---|---|---|
| Patient group | pN/M | pT | IL-6 | IL-6R | No. (%) | 5-year CSS (%) | 10-year CSS (%) |
| pT-IL-6-IL-6R low risk | pN0 and M0 | 1–2 | − | − | 38 (20.2%) | 97.1±2.9 | 87.2±6.0 |
| 1–2 | − | + | 44 (23.4%) | 93.1±3.9 | 85.3±5.6 | ||
| 1–2 | + | − | 23 (12.2%) | 90.2±6.6 | 81.2±10.4 | ||
| pT-IL-6-IL-6R high risk | pN0 and M0 | 1–2 | + | + | 33 (17.6%) | 61.9±8.7 | 47.7±10.0 |
| 3–4 | − | − | 10 (5.3%) | 70.0±14.5 | 50.0±15.8 | ||
| 3–4 | − | + | 14 (7.4%) | 64.3±12.8 | 50.0±13.4 | ||
| 3–4 | + | − | 9 (4.8%) | 55.6±16.6 | 41.7±17.3 | ||
| 3–4 | + | + | 9 (4.8%) | 44.4±16.6 | 11.1±10.5 | ||
| Metastatic | pN1 or M1 | Any | Any | Any | 8 (4.3%) | 12.5±11.7 | 12.5±11.7a |
Abbreviations: CSS=cancer-specific survival; IL=interleukin; IL-6R=interleukin-6 receptor.
a
The largest survival time is censored.